NASDAQ : HALO
Halozyme Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 130.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.86B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.64B |
| Enterprise Value | 16.58B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 113.50M |
| Shares Outstanding | 113.50M |
| Shares Change (YoY) | -4.21% |
| Shares Change (QoQ) | -1.35% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 111.83% |
| Float | 112.19M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 38.13 |
| Forward PE | 12.95 |
| PS Ratio | 8.80 |
| Forward PS | 7.20 |
| PB Ratio | 104.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.15 |
| P/OCF Ratio | 17.88 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 40.09 |
| EV / Sales | 9.97 |
| EV / EBITDA | 15.78 |
| EV / EBIT | 17.56 |
| EV / FCF | 20.57 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.71 |
| Quick Ratio | 1.99 |
| Debt / Equity | 15.18 |
| Debt / EBITDA | 2.05 |
| Debt / FCF | 2.70 |
| Interest Coverage | 46.52 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 173.67% |
| Return on Assets (ROA) | 25.49% |
| Return on Invested Capital (ROIC) | 32.13% |
| Return on Capital Employed (ROCE) | 42.30% |
| Weighted Average Cost of Capital (WACC) | 7.99% |
| Revenue Per Employee | $3.93M |
| Profits Per Employee | $977,768 |
| Employee Count | 423 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 2.48 |
Taxes
| Measure | Value |
|---|
| Income Tax | 169.74M |
| Effective Tax Rate | 29.10% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +97.81% |
| 50-Day Moving Average | 114.12 |
| 200-Day Moving Average | 83.66 |
| Relative Strength Index (RSI) | 71.46 |
| Average Volume (20 Days) | 2,189,725 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 13.65M |
| Short Previous Month | 15.30M |
| Short % of Shares Out | 12.03% |
| Short % of Float | 12.17% |
| Short Ratio (days to cover) | 4.97 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.66B |
| Gross Profit | 1.27B |
| Operating Income | 944.49M |
| Pretax Income | 583.34M |
| Net Income | 413.60M |
| EBITDA | 1.05B |
| EBIT | 944.49M |
| Earnings Per Share (EPS) | $3.38 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 231.00M |
| Total Debt | 2.18B |
| Net Cash | -1.95B |
| Net Cash Per Share | -$17.16 |
| Equity (Book Value) | 143.54M |
| Book Value Per Share | 1.26 |
| Working Capital | 588.59M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 818.60M |
| Capital Expenditures | -12.37M |
| Depreciation & Amortization | 106.20M |
| Net Borrowing | 624.57M |
| Free Cash Flow | 806.22M |
| FCF Per Share | $7.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | 76.27% |
| Operating Margin | 56.77% |
| Pretax Margin | 35.06% |
| Profit Margin | 24.86% |
| EBITDA Margin | 63.15% |
| EBIT Margin | 56.77% |
| FCF Margin | 48.46% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 4.21% |
| Shareholder Yield | 4.21% |
| Earnings Yield | 2.62% |
| FCF Yield | 5.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $108.78 |
| Price Target Difference | -15.64% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 18.75% |
| EPS Growth Forecast (3Y) | 42.80% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 10, 2003 |
| Split Type | Forward |
| Split Ratio | 4.275:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |